Personalized radiation based on tumor genetics in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age 18 or older)
- You have triple-negative breast cancer confirmed by a biopsy (no HER2 overexpression; very low estrogen/progesterone receptors)
- You previously had breast-conserving surgery (lumpectomy) with checking underarm lymph nodes (sentinel biopsy or dissection), and you recovered enough to start (often within 14 days)
- Your doctors must be able to use your existing tissue samples to calculate the “RSI” score used by the study
- You should not have spread breast cancer to distant organs (no metastatic disease)
- You must have enough time to be on the study (life expectancy over 16 weeks) and be able to do daily activities at a moderate level (KPS 70 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
This study tests whether a new approach using a genetic test can guide treatment for low-risk triple-negative breast cancer. It aims to help patients avoid unnecessary chemotherapy while keeping the cancer from coming back.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.